Journal
SEMINARS IN IMMUNOPATHOLOGY
Volume 42, Issue 5, Pages 619-634Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00281-020-00821-0
Keywords
COVID-19; SARS-CoV-2; Vaccination; Older population; Immunosenescence; Inflammaging
Categories
Funding
- Universita degli Studi di Siena within the CRUI-CARE Agreement
- Commission of the European Communities, Horizon 2020 Framework Programme [730964]
- Russian Ministry of Science and Education [075-15-2020-808]
Ask authors/readers for more resources
The SARS-CoV-2 pandemic urgently calls for the development of effective preventive tools. COVID-19 hits greatly the elder and more fragile fraction of the population boosting the evergreen issue of the vaccination of older people. The development of a vaccine against SARS-CoV-2 tailored for the elderly population faces the challenge of the poor immune responsiveness of the older population due to immunosenescence, comorbidities, and pharmacological treatments. Moreover, it is likely that the inflammaging phenotype associated with age could both influence vaccination efficacy and exacerbate the risk of COVID-19-related cytokine storm syndrome with an overlap between the factors which impact vaccination effectiveness and those that boost virulence and worsen the prognosis of SARS-CoV-2 infection. The complex and still unclear immunopathological mechanisms of SARS-CoV-2 infection, together with the progressive age-related decline of immune responses, and the lack of clear correlates of protection, make the design of vaccination strategies for older people extremely challenging. In the ongoing effort in vaccine development, different SARS-CoV-2 vaccine candidates have been developed, tested in pre-clinical and clinical studies and are undergoing clinical testing, but only a small fraction of these are currently being tested in the older fraction of the population. Recent advances in systems biology integrating clinical, immunologic, and omics data can help to identify stable and robust markers of vaccine response and move towards a better understanding of SARS-CoV-2 vaccine responses in the elderly.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available